Synthesis 2012; 44(10): 1556-1558
DOI: 10.1055/s-0031-1290947
short paper
© Georg Thieme Verlag Stuttgart · New York

A Practical Synthesis of Alendronate Sodium through Counterattack Reaction

Masahiko Seki*
Mitsubishi Tanabe Pharma Corporation, 2-6-18, Kitahama, Chuo-ku, Osaka 541-8505, Japan, eMail: seki.masahiko@mm.mt-pharma.co.jp
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 13. Februar 2012

Accepted after revision: 14. März 2012

Publikationsdatum:
19. April 2012 (online)


Abstract

An efficient synthesis of alendronate sodium, an osteoporosis drug, has been developed through ‘counterattack reaction’ involving treatment of the respective acyl phosphonate with (MeO)3P and TMSBr followed by deblocking with aqueous HCl.

 
  • References

  • 2 Lidor-Hadas R, Lifshitz R (Teva Pharmaceutical Industries Ltd.) Patent WO 2000049026, 2000 ; Chem. Abstr. 2000, 133, 1773
    • 3a Kieczykowski GR, Jobson RB, Melillo DG, Reinhold DF, Grenda VJ, Shinkai I. J. Org. Chem. 1995; 60: 8310
    • 3b Singh GP, Jadhay HS, Maddireddy NY, Srivastava D , Lupin Ltd., Patent WO 2007010556, 2007 ; Chem. Abstr. 2007, 146, 142830
    • 3c Senthikumer UP, Arulmoli T, Lakshmipathi VS, Rao SM (Orchid Chemicals & Pharmaceuticals Ltd.) Patent WO 2008035131, 2008 ; Chem. Abstr. 2008, 148, 331840
    • 3d Mandava VN. B. R, Setty RK. S, Manne N (Dr. Reddy’s Laboratories) US Patent 20070142636, 2007 ; Chem. Abstr. 2007, 147, 53018
  • 7 Karaman R, Goldblum A, Breuer E, Leader H. J. Chem. Soc., Perkin Trans. 1 1989; 765
  • 8 Fridman YaD, Kebets NM, Nanaeba MT, Zurdinov AZ, Sabirova TS, Atarskaya LI. Pharm. Chem. J. 1989; 23: 879